Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) and Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.
Earnings and Valuation
This table compares Crinetics Pharmaceuticals and Sonoma Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crinetics Pharmaceuticals | $7.70 million | 1,170.54 | -$465.32 million | ($5.04) | -16.86 |
| Sonoma Pharmaceuticals | $19.53 million | 0.31 | -$3.17 million | ($1.22) | -1.02 |
Profitability
This table compares Crinetics Pharmaceuticals and Sonoma Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crinetics Pharmaceuticals | -1,189.88% | -44.22% | -39.77% |
| Sonoma Pharmaceuticals | -10.33% | -21.41% | -6.08% |
Analyst Ratings
This is a summary of current ratings for Crinetics Pharmaceuticals and Sonoma Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crinetics Pharmaceuticals | 1 | 11 | 5 | 0 | 2.24 |
| Sonoma Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Crinetics Pharmaceuticals presently has a consensus price target of $81.00, suggesting a potential downside of 4.65%. Given Crinetics Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Crinetics Pharmaceuticals is more favorable than Sonoma Pharmaceuticals.
Insider and Institutional Ownership
98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.9% of Sonoma Pharmaceuticals shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Crinetics Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
Summary
Sonoma Pharmaceuticals beats Crinetics Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
